Ser Ling Chua

Ser Ling Chua

Auto-generated profile, based on publicly available information

Ser Ling Chua

University Hospital Birmingham NHS Foundation Trust , Birmingham

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in JAAD Case Reports
Verified
Journal Article
Open access
AWAaron Giles Wernham
Aaron Giles Wernham
BVBindu Vydianath
Bindu Vydianath
SCSer Ling Chua
Ser Ling Chua

12 September 2012
Verified
Reference Entry
Closed access
PDF file
JIJohn R Ingram
John R Ingram
NDNemesha Desai
Nemesha Desai
AKAnneke C Kai
Anneke C Kai
SCSer Ling Chua
Ser Ling Chua
PWPick-Ngor Woo
Pick-Ngor Woo
VPVincent Piguet
Vincent Piguet

15 May 2025 in British Journal of Dermatology
Verified
Journal Article
Closed access
JPJames B Powell
James B Powell
JDJugdeep K Dhesi
Jugdeep K Dhesi
CHCatherine A Harwood
Catherine A Harwood
EMEmily J McGrath
Emily J McGrath
ZVZoe C Venables
Zoe C Venables
MMM Firouz Mohd Mustapa
M Firouz Mohd Mustapa
The British Association of Dermatologists and British Geriatrics Society recommend routine screening for frailty for all patients aged ≥ 65 years being considered for management of skin cancer using a validated tool such as the Rockwood Clinical Frailty Scale.

5 March 2026 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
GMGeorge W M Millington
George W M Millington
PPPriya U Patel
Priya U Patel
SCSer-Ling Chua
Ser-Ling Chua
ABAnthony Bewley
Anthony Bewley
JSJane C Sterling
Jane C Sterling
ZKZahra Mansour Kiaee
Zahra Mansour Kiaee
Lay Summary: Nodular prurigo (NP) is a chronic skin condition. Lesions can be either single or widespread on the body. Thus, it can have a negative impact on a person’s quality of life. The exact cause of NP is unknown, as several mechanisms play a role. These mechanisms sometimes overlap between physical and brain–behavioural elements. Dermatologists diagnose NP based on a history of long-lasting itching and scratching. A Guideline Development Group met to produce a new guideline for treating people with NP. The group included consultant dermatologists, a psychotherapist, dermatology trainees, a general practitioner and people with lived experience of NP. The group identified and reviewed the current literature on treating NP. They discussed the findings at length before producing a set of recommendations. The guideline will provide up-to-date management guidance for healthcare practitioners. Initial steps included taking a full history and examination of patients. This included causes of itch, patient education and reversing the itch–scratch habit. The first treatment option is usually topical therapy (applied to the skin). If this fails, other options include phototherapy and oral medications. Further treatments include nonsedating antihistamines and low-dose antidepressants. Steroid injections or cryotherapy (freezing with liquid nitrogen) are options for single lesions. The guideline provides recommendations for treating people with NP. It also includes recommendations for future research and audit points for hospitals. A patient information leaflet is available on the British Association of Dermatologists’ website (https://www.skinhealthinfo.org.uk/condition/nodular-prurigo).

28 January 2026 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
HWHannah E Wainman
Hannah E Wainman
SCSer Ling Chua
Ser Ling Chua
DODonal O’KAne
Donal O’KAne
SMSarah Mehrtens
Sarah Mehrtens
JIJohn R Ingram
John R Ingram
We conducted a retrospective cohort study across four UK centres to establish whether therapeutic drug monitoring and dose escalation of adalimumab up to 80 mg weekly improved patient outcomes. This study represents one of the largest cohorts examining therapeutic drug monitoring and high-dose adalimumab in patients with hidradenitis suppurativa. Unlike previous studies, we did not observe significant mean improvements across standardized outcome measures, despite over 50% of patients being assessed by their clinicians as showing overall improvement.

25 April 2025 in British Journal of Dermatology
Verified
Journal Article
Closed access
ACAlina M Constantin
Alina M Constantin
RMRuth Murphy
Ruth Murphy
RMRobert J Moots
Robert J Moots
MHMatthew J Harries
Matthew J Harries
SCSer-Ling Chua
Ser-Ling Chua
MMM Firouz Mohd Mustapa
M Firouz Mohd Mustapa
Reply to ‘Enhance the transparency in the development of the BAD living guidelines’ by Liu et al.